Corcept Therapeutics (CORT) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Corcept Therapeutics (NASDAQ: CORT) recently:

• 6/2/2026 – Corcept Therapeutics had its price target raised by HC Wainwright from $75.00 to $95.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Corcept Therapeutics was given a new $135.00 price target by UBS Group AG.
• 5/28/2026 – Corcept Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $110.00 to $135.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Corcept Therapeutics had its price target raised by HC Wainwright from $75.00 to $95.00. They now have a “buy” rating on the stock.
• 5/13/2026 – Corcept Therapeutics was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $72.00 price target on the stock, up from $44.00.
• 5/4/2026 – Corcept Therapeutics had its price target raised by HC Wainwright from $60.00 to $75.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Corcept Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 5/1/2026 – Corcept Therapeutics had its price target raised by Piper Sandler from $73.00 to $88.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 75,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the transaction, the insider owned 8,977 shares in the company, valued at approximately $588,801.43. This represents a 89.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of the company’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief executive officer owned 2,918,326 shares in the company, valued at $146,120,582.82. This represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 242,965 shares of company stock worth $14,802,964. 20.70% of the stock is owned by company insiders.

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.